<DOC>
	<DOCNO>NCT01548703</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics pharmacodynamics BCI-838 metabolite BCI-632 healthy male female subject .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study BCI-838 Healthy Volunteers</brief_title>
	<detailed_description>This study evaluate safety tolerability follow oral administration multiple dose BCI-838 healthy male female subject . The pharmacokinetic profile multiple oral dos BCI-838 healthy male female subject also assess . In addition , pharmacodynamic effect BCI-838 central nervous system use quantitative electroencephalogram analysis study .</detailed_description>
	<criteria>Adult male female healthy volunteer , 1855 year age Body Mass Index ( BMI ) 18.0 30.0 kg/m2 inclusive Female subject must negative pregnancy test screen admission . Females childbearing potential ( least 2 year postmenopausal surgically sterile ) must use reliable , medically acceptable form contraception least 30 day prior screen visit must agree continue use throughout duration study 3 month final dose study drug . Good general health determine medical history physical examination clinically significant medical finding clinically relevant medical surgical history acute ongoing condition within past 30 day Able participate willing give write informed consent comply study restriction Clinically significant medical abnormality , chronic disease history presence significant pulmonary , gastrointestinal , metabolic , cardiac , hepatic , renal neurological disorder History current use alcohol abuse drug addiction Participation drug study within 60 day prior drug administration . Participation 3 drug study 10 month precede start study Donation blood loss 50 mL blood within 60 day prior first drug administration . Donation 1.5 liter blood 10 month precede start study Illness within 5 day prior drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>metabotropic glutamate receptor 2 3</keyword>
	<keyword>antagonist</keyword>
	<keyword>mGluR</keyword>
	<keyword>ketamine</keyword>
	<keyword>BDNF</keyword>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Treatment Resistant Depression</keyword>
	<keyword>Mood Disorder</keyword>
	<keyword>Phase 1 safety , tolerability pharmacokinetics study</keyword>
</DOC>